Athena Athena

X
[{"orgOrder":0,"company":"Kamari Pharma","sponsor":"GIBF2","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kamari Pharma Raises $8 Million from the Sino-Israeli GIBF2 Fund","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by Kamari Pharma

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The company develops topical and oral drugs based on proprietary small molecules that inhibit an ion channel designated TRPV3. These drugs are intended for the treatment of various dermatological diseases.

            Lead Product(s): Undisclosed

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: GIBF2

            Deal Size: $8.0 million Upfront Cash: Undisclosed

            Deal Type: Financing September 19, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY